Open AccessFORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF DROTAVERINE HYDROCHLORIDE USING MERCURY SUBSTRATE METHOD
Author(s) -
Kunal V Bhambar
Publication year - 2021
Publication title -
journal of medical pharmaceutical and allied sciences
Language(s) - English
Resource type - Journals
ISSN - 2320-7418
DOI - 10.22270/jmpas.v10i6.2096
Subject(s) - transdermal , folding endurance , chemistry , plasticizer , transdermal patch , fourier transform infrared spectroscopy , chromatography , first pass effect , differential scanning calorimetry , ethyl cellulose , pharmacology , bioavailability , nuclear chemistry , organic chemistry , chemical engineering , polymer , medicine , physics , engineering , thermodynamics
Aim of the present investigation is to prepare sustained release transdermal patches of Drotaverine hydrochloride. Transdermal drug delivery has ability to bypass liver first pass metabolism and deliver the drug towards systemic circulation. Drotaverine hydrochloride is used to treat the spasticity as muscle relaxant. Mercury substrate method is utilized for formulation of Transdermal patches of Drotaverine Hydrochloride. Ethyl cellulose and Eudragit RL 100 were used to retard the drug release. Dibutyl phthalate used as plasticizer and Dichloromethane as a solvent system. Transdermal patches were evaluated for physical appearance, weight variation, drug content, folding endurance, Fourier-transform infrared spectroscopy (FTIR), Differential scanning colourimetry (DSC) and invitro drug release study. The DSC curve of transdermal patch (TDDS D3) shows a sharp endothermic peak at 208.17°C indicating crystalline structure. The dissolution curve shows that formulation TDDS D3 shows maximum drug release 83.57% at the end of 12 Hrs. For transdermal patches according to ‘r’ value, Korsmeyer- Peppas model was best suited for drug release but n value obtained from Kors Meyer- Peppa’s equation was within 0.5 -1.0 which indicates anomalous releases